Last updated: April 23, 2026
Who Supplies Indium In-111 Oxyquinoline (In-111 Oxine)?
Indium In-111 oxyquinoline (often marketed as In-111 oxine, indium In-111 saturnine/oxine, or Indium (111) oxine) is a specialized radiopharmaceutical product. The market is structured around a limited set of suppliers that control (1) indium-111 radionuclide supply, (2) radiopharmaceutical manufacturing, and (3) global distribution through nuclear medicine channels.
What are the supplier routes (and who supplies each)?
Indium In-111 oxine is not sourced like a standard small-molecule API. It is typically supplied through one of these routes:
-
Nuclear medicine radiopharmacy supply chain (US/EU standard)
- Manufacturer supplies a radio-labeled kit or finished radiopharmaceutical to certified radiopharmacies.
- Radiopharmacies prepare dosing for hospitals/nuclear medicine clinics.
-
Radiopharmaceutical company + radionuclide procurement
- Manufacturer procures In-111 from radionuclide production networks and then formulates and labels the final product.
-
Government/utility radionuclide production (regional backbone)
- In-111 production is handled by specialized production facilities; radiopharmacies and radiopharmaceutical manufacturers do downstream labeling/manufacturing.
Which companies supply Indium In-111 oxyquinoline?
Based on publicly available global product listings and radiopharmaceutical supplier catalogs, the supplier set for Indium In-111 oxyquinoline includes the following categories and named entities:
1) Global radiopharmaceutical manufacturers with In-111 oxine products
- Nordion (now part of Sterigenics/Nordion assets have been reorganized under different labels over time)
- GE Healthcare (radiopharmacy and radiopharmaceutical manufacturing ecosystem)
- Mallinckrodt / Cardinal Health radiopharmaceutical distribution networks (varies by geography and labeling)
- CIS Bio / Groupe CIS Bio (distribution presence varies by market)
- B. Braun (radiopharmaceutical supply presence in multiple EU markets)
2) Regional nuclear medicine distributors and radiopharmacy suppliers
- Cardinal Health (distribution and radiopharmacy products in the US)
- McKesson (distribution and radiopharmacy channel presence in the US)
- Local certified radiopharmacies (final order and preparation for hospitals)
What do you actually buy from suppliers?
For most customers, the purchase item is one of these:
- A kit (or closed system) that a licensed radiopharmacy reconstitutes/labels with Indium-111
- A finished radiopharmaceutical dose supplied ready for patient administration
The supplier decides which format is offered by market and regulatory pathway.
Supplier Comparison by Market Access
Who supplies in the US channel?
In the US, access typically comes through:
- Radiopharmaceutical manufacturers with authorized distribution for In-111 labeled products
- Certified radiopharmacies that receive product and prepare patient doses
US supply is usually dominated by large distribution networks serving hospitals and nuclear medicine centers, with product manufacture tied to companies that hold approvals and commercial packaging/labeling rights.
Who supplies in the EU/UK channel?
In the EU/UK, supply typically flows through:
- Radiopharmaceutical manufacturers with MA/marketing authorizations in member states
- Distribution via hospital pharmacy channels and radiopharmacy operators
- Local/regional importers for specific presentations
How to qualify suppliers for Indium In-111 oxyquinoline (practical due diligence)
What supplier criteria matter for R&D or procurement?
Use these qualification checks when selecting suppliers:
- Regulatory status in target country (marketing authorization or approved imported product)
- Batch release model (who releases the batch and where release testing happens)
- Delivery format (kit vs ready-to-use dose)
- Radionuclide procurement capability (ability to secure In-111 activity on schedule)
- Supply lead time for radiopharmaceutical logistics (short shelf-life constraints)
Key Takeaways
- Indium In-111 oxyquinoline is supplied through a radiopharmaceutical supply chain, not typical API sourcing.
- Supplier availability depends on regional regulatory approvals and certified radiopharmacy distribution.
- In practice, you select suppliers by product format (kit vs finished dose), regulatory status, and In-111 supply reliability through nuclear medicine networks.
FAQs
1) Is Indium In-111 oxyquinoline a standard chemical API commodity?
No. It is a radiolabeled diagnostic product that is supplied via radiopharmaceutical manufacturing and licensed nuclear medicine distribution channels.
2) Do suppliers sell Indium In-111 oxyquinoline as a kit or ready-to-dose?
Both models exist by market and supplier, with hospitals often receiving prepared doses from certified radiopharmacies.
3) Who controls supply continuity for In-111 oxyquinoline?
Continuity depends on the radionuclide supply for Indium-111 and downstream radiopharmaceutical labeling/manufacturing capacity.
4) Can I source it directly from chemical suppliers?
For commercial clinical use, supply typically comes through radiopharmaceutical manufacturers and authorized distributors, not commodity chemical channels.
5) What is the fastest route to procurement?
Ordering is usually routed through certified radiopharmacies or hospital radiopharmacy services that have established supplier accounts and logistics for short-lived radiopharmaceuticals.
References (APA)
[1] FDA. (n.d.). Radiopharmaceutical drug products and application information. U.S. Food and Drug Administration. https://www.fda.gov/
[2] EMA. (n.d.). Human medicines: marketing authorisation. European Medicines Agency. https://www.ema.europa.eu/
[3] IAEA. (n.d.). Radionuclides and radioisotope production. International Atomic Energy Agency. https://www.iaea.org/
[4] Nuclear Regulatory Commission. (n.d.). Materials licensing and radiopharmaceuticals (overview). U.S. Nuclear Regulatory Commission. https://www.nrc.gov/
